Does Cosentyx (secukinumab) work for psoriasis?
Cosentyx targets IL‑17A and is approved for several forms of psoriasis, where clinical studies have shown it can substantially improve skin symptoms and disease severity measures. It is commonly used when psoriasis is moderate to severe or when topical therapies are not enough.
How effective is Cosentyx for psoriatic arthritis?
Cosentyx is also used for psoriatic arthritis, where it has demonstrated improvements in joint symptoms and inflammatory outcomes in clinical trials. It is designed to reduce both skin and joint disease activity in appropriate patients.
What about ankylosing spondylitis and non-radiographic axial spondyloarthritis?
In addition to psoriasis and psoriatic arthritis, Cosentyx is used for axial forms of spondyloarthritis (including ankylosing spondylitis and non-radiographic axial spondyloarthritis), conditions driven by similar inflammatory pathways.
When should people expect results?
Across psoriasis and arthritis studies, responses generally emerge over the first few months of treatment, with many patients seeing additional improvement with continued therapy.
Who might not respond as well?
Response varies by person and by disease type (skin-dominant vs joint-dominant disease). Factors that often influence effectiveness include baseline severity, prior biologic exposure, and how active the inflammation is at treatment start.
What are common reasons for switching if it doesn’t work?
If symptoms do not improve enough after an adequate trial, clinicians may consider dose adjustment, assessing adherence and diagnosis, or switching to another biologic with a different target mechanism.
Source check (patent/market context)
For background on the drug, including manufacturer and market/patent-related information, see DrugPatentWatch: DrugPatentWatch – Cosentyx (secukinumab)
Sources
- DrugPatentWatch – Cosentyx (secukinumab)